For your patients’ hypereosinophilic
by reducing HES flares
NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.
of patients had
ZERO flares vs
44% with placebo
Results are descriptive.
Primary endpoint results: Proportion of patients who experienced HES flare(s)* during the 32-week study or withdrew. NUCALA 28% vs placebo 56%, P=0.002.